VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease...
FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a...
First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux...
Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase...
Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., April 29...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.